Abiomed posts 33 percent increase in revenue as Impella devices gain market momentum
Danvers, Massachusetts-based Abiomed has posted a 33 percent increase in total sales in its fourth quarter, which exceeded market watchers’ expectations, reported The Motley Fool.
Abiomed raked in $124.7 million in the fourth quarter of this year, compared with $94 million in 2016. Adjusted earnings per share are $.033, compared to $0.24 the same time last year.
The company attributes the growth to increasing sales of its Impella heart pumps.
To read the full story, follow the link below:
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.